Peptide library

Topical GHK-Cu

GHK-Cu, also called copper tripeptide-1, is a common cosmetic ingredient. The human studies of skin products are small, and most were never published as full papers.

Short answerCompound research · 5 min read · Updated 18 Nov 2026

As a skin-care ingredient, GHK-Cu has been tested in people only in small studies, mostly reported at conferences or in minor journals; the one PubMed-indexed randomised trial, after laser resurfacing, found no objective difference. We found no large, independent randomised trial. In the US, cosmetics need no FDA approval before sale, unless their intended use makes them drugs.

Key takeaways

  • GHK-Cu is the copper(II) complex of the tripeptide glycyl-histidyl-lysine, also called copper tripeptide-1 or prezatide copper.
  • The human skin studies are small; most were conference posters or pilot reports, known through a 2018 review by GHK’s discoverer.
  • The one PubMed-indexed randomised trial of a skin-care regimen, after laser resurfacing, found no objective difference; patients rated their skin quality higher.
  • Topical results do not apply to injected GHK-Cu, for which FDA says human data are limited.
  • In the US, cosmetics need no approval before sale, but a product intended to affect the body’s structure or function is a drug.

01Topical GHK-Cu at a glance

Skin-applied GHK-Cu only. The compound’s wider research is on the GHK-Cu research guide.

QuestionTopical GHK-Cu
What it isThe copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine. GHK was isolated from human plasma in 1973.
Other namesCopper tripeptide-1; prezatide copper; GHK copper
Human evidence for skin-care useT2: small studies, most reported at conferences or in minor journals and known through a 2018 review by GHK’s discoverer; one PubMed-indexed randomised trial of a skin-care regimen, with 13 completers
Registered studies4 apply a product containing GHK-Cu to skin, 3 of them with other active ingredients; none has posted results (ClinicalTrials.gov, 18 Nov 2026)
United StatesCosmetics, except colour additives, need no FDA approval before sale; a product intended to affect the body’s structure or function is a drug
United KingdomThe MHRA treats cosmetics as possible borderline products and decides whether claims or ingredients make one a medicine
AustraliaThe TGA’s April 2026 advisory names GHK-Cu among examples of unapproved peptide products
WADANot named on the 2026 or 2027 List; WADA says a peptide not specifically named “may still be prohibited”
Injected formFDA: limited human data and a possible risk of immune reactions; we found no controlled trial of it

02What human studies have tested GHK-Cu skin products?

Most of what is said about GHK-Cu in skin care traces to a handful of small studies. Here is each one, where it appeared, and whether we could read it.

StudyDesign and peopleWhat was measuredWhere it appearedRead in full by us
Leyden et al., 2002Facial cream, 12 weeks, 71 women with signs of photoageingSkin density and thickness, laxity, clarity, fine lines, wrinkle depthConference poster, American Academy of DermatologyNo; known through the 2018 review
Leyden et al., 2002Eye cream, 12 weeks, 41 women, compared with placebo and a vitamin K creamLines and wrinkles, skin density and thicknessConference posterNo
Abdulghani et al., 1998Pilot on thigh skin, 12 weeks, compared with vitamin C cream and tretinoinCollagen productionDisease Management and Clinical OutcomesNo
Badenhorst et al., 2016Randomised, double-blind, 8 weeks, female volunteers; GHK-Cu in a nano-lipid carrier against carrier alone and another peptide productWrinkle volume and depthJournal of Aging ScienceNo
Miller et al., 2006Randomised, after CO2 laser resurfacing around the mouth; 13 completedRedness, wrinkles, overall skin quality, patient questionnaireArchives of Facial Plastic SurgeryAbstract

We could not read the first four in full; what is known of them comes from the 2018 review (T2). The one PubMed-indexed randomised trial of a skin-care regimen did not find an objective difference: in Miller 2006, computer analysis and blinded evaluators found no significant difference in redness, wrinkles or overall skin quality, though patients using GHK-Cu products rated their skin quality higher.

Two cautions apply to all of them. They are small and short. And the evidence base is concentrated: a 2026 systematic review found that about 35% of the GHK-Cu primary literature it included lists Loren Pickart or Anna Margolina of Skin Biology Inc. as authors, and noted that Pickart, who first isolated GHK, held commercial interests in the field for decades. The 2018 review that summarises the skin studies is theirs. The same 2026 review describes the human literature as “thin and fragmented”, with most randomised trials small and of facial cosmetic creams.

03What studies of topical GHK-Cu are registered?

On 18 November 2026, ClinicalTrials.gov listed four studies that apply a product containing GHK-Cu to skin, none with posted results. NCT07437586 is a phase 2, randomised, vehicle-controlled, double-blind study planned for 60 healthy adults, each with two small standardised skin wounds; it measures time to complete re-growth of the skin surface and has been recruiting since February 2026. NCT07888595 is an early phase 1 study planned for 48 adults, using a multi-peptide serum with untreated skin sites as controls and measuring markers of biological age; it is enrolling by invitation. Two completed single-group studies tested multi-ingredient products that include it: NCT05932732, three professional facial treatments using a serum that lists copper peptide among its ingredients (27 adults, completed October 2024), and NCT07879833, a skincare regimen whose night creams include copper tripeptide-1 (43 women, completed February 2026). Neither can separate GHK-Cu’s contribution from the other ingredients.

Another record, NCT07706361, measures blood GHK and GHK-Cu levels after a skin patch and is not yet recruiting.

04Do topical GHK-Cu studies apply to injected GHK-Cu?

The topical studies say nothing about injected GHK-Cu. FDA’s compounding page says compounded injectable drugs containing GHK-Cu “may pose risk for immunogenicity due to the potential for aggregation and peptide-related impurities” and that “there are limited data in humans to inform safety-related considerations”. We found no controlled trial of injected GHK-Cu, published or registered (PubMed and ClinicalTrials.gov, 18 November 2026).

05How do cosmetic and medicines rules treat GHK-Cu?

United States. FDA says that “cosmetic products and ingredients, with the exception of color additives, do not require FDA approval before they go on the market”. Whether a product is a cosmetic or a drug “is determined by a product’s intended use”, and claims count: FDA gives claims that a product will “regenerate cells” as an example of what makes a product a drug.

United Kingdom. The MHRA lists cosmetics among “borderline products” and decides whether “the claims that are made or the active substance(s) present” mean a product should be regarded as a medicinal product (guidance updated 2 July 2026).

Australia. The TGA’s April 2026 safety advisory names GHK-Cu, with BPC-157, TB-500, retatrutide and CJC-1295, among examples of unapproved peptide products, “often supplied in injectable form”. We read it on the Internet Archive capture of 10 August 2026, because tga.gov.au did not respond to us. We have not verified how Australian rules treat a cosmetic containing GHK-Cu.

Sport. GHK-Cu is not named on WADA’s 2026 or 2027 Prohibited List. Class S0 covers any pharmacological substance not addressed elsewhere on the List and “with no current approval by any governmental regulatory health authority for human therapeutic use”. WADA’s notes on the 2027 List add that “even if a peptide is not specifically named on the List, utmost caution should be taken as it may still be prohibited and may be harmful to health”. Anti-doping organisations decide how the List applies. See peptides and anti-doping.

06What doesn’t topical GHK-Cu research show?

  • A result from a large, independent, randomised trial of a GHK-Cu skin-care product. We found none.
  • How much intact peptide reaches the deeper skin from a cosmetic product in people. We found no study in people that measured it.
  • Long-term effects, or how often uncommon skin reactions occur. The studies were small and short, and we found no published case report of a reaction to topical GHK-Cu (PubMed, 18 Nov 2026).
  • Anything about injected GHK-Cu, a different route with no controlled human data.

Why the powder and solutions are blue, and what that colour can and cannot tell you: why is GHK-Cu blue?

This is a plain-English summary of public documents and studies, checked on 18 Nov 2026. It is not legal or medical advice.

RefSources

  1. Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci, 2018;19(7):1987. PMID 29986520. pmc.ncbi.nlm.nih.gov/articles/PMC6073405/
  2. Miller TR, Wagner JD, Baack BR, Eisbach KJ. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg, 2006;8(4):252–259. PMID 16847171. pubmed.ncbi.nlm.nih.gov/16847171/
  3. Najafi N, Maatouk H, Vardanyan KG, et al. A systematic review of the mechanisms and therapeutic applications of GHK-Cu (glycyl-L-histidyl-L-lysine-copper complex) in topical microneedle delivery: a case for expanded clinical trials. Arch Intern Med Res, 2026;9(3):269–293. PMID 42787770. pubmed.ncbi.nlm.nih.gov/42787770/
  4. ClinicalTrials.gov. Search results for “GHK-Cu” and “copper tripeptide-1”: NCT07437586, NCT07888595, NCT05932732, NCT07879833, NCT07706361. Registry search and records, read 18 Nov 2026. clinicaltrials.gov/search?term=GHK-Cu
  5. U.S. Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks. Web page, content current as of 22 Apr 2026; read 18 Nov 2026. www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-s…
  6. U.S. Food and Drug Administration. Is it a cosmetic, a drug, or both? (Or is it soap?). Web page, content current as of 11 Sep 2024; read 18 Nov 2026. www.fda.gov/cosmetics/cosmetics-laws-regulations/it-cosmetic…
  7. Medicines and Healthcare products Regulatory Agency. Borderline products: how to tell if your product is a medicine. Guidance, last updated 2 Jul 2026; read 18 Nov 2026. www.gov.uk/guidance/borderline-products-how-to-tell-if-your-…
  8. Therapeutic Goods Administration. Understanding your responsibilities when importing, compounding and supplying unapproved peptide products. Safety advisory, 13 Apr 2026; read on the Internet Archive capture of 10 Aug 2026 (tga.gov.au timed out on 18 Nov 2026). www.tga.gov.au/safety/safety-monitoring-and-information/safe…
  9. PubChem. Prezatide copper, CID 71587328: synonyms include copper tripeptide-1 and GHK copper. Compound record, read 18 Nov 2026. pubchem.ncbi.nlm.nih.gov/compound/71587328
  10. World Anti-Doping Agency. Prohibited List 2026 (in force 1 Jan 2026) and Prohibited List 2027 (in force 1 Jan 2027), both PDFs read 18 Nov 2026; and 2027 Prohibited List: summary of major modifications and explanatory notes (S0). International Standard and explanatory note; read 18 Nov 2026. www.wada-ama.org/en/prohibited-list

Plain-English summary of public sources, not legal or medical advice. Last checked 18 Nov 2026.

Questions

Does topical GHK-Cu have human studies?

Small ones, for skin-care use. Most were conference posters or pilot studies; the one PubMed-indexed randomised trial of a skin-care regimen, with 13 completers after laser resurfacing, found no objective difference from the comparison routine.

Is GHK-Cu the same as copper tripeptide-1?

Yes. Copper tripeptide-1 and prezatide copper are other names for the copper complex of glycyl-histidyl-lysine.

Is topical GHK-Cu the same as injected GHK-Cu?

Same molecule, different evidence. The human studies are of skin products; FDA says there are limited human data on injectable GHK-Cu, and we found no controlled trial of it.

Does a cosmetic with GHK-Cu need FDA approval?

Not as a cosmetic: FDA says cosmetics and their ingredients, apart from colour additives, need no approval before sale. A product intended to affect the structure or function of the body is regulated as a drug.

Is GHK-Cu on the WADA Prohibited List?

It is not named on the 2026 or 2027 List. Class S0 covers pharmacological substances with “no current approval by any governmental regulatory health authority for human therapeutic use”. WADA’s notes on the 2027 List add that a peptide not specifically named “may still be prohibited”; anti-doping organisations decide how the List applies.

Evidence before hype.

One email a week: new research explained and regulatory changes. No prices, no hype.

Get the 6:00 brief

Free. Unsubscribe any time.

Written by 6AM Research. Drafted from primary sources; every claim links to its source, and the page is dated. Editorial policy · How we check every page